Examkin

Soru

Zorluk: OrtaNormal Pregnancy and Prenatal Care

Standard prenatal care involves a strict schedule of laboratory evaluations and prophylactic interventions based on gestational age to optimize maternal and fetal outcomes. Match each clinical presentation during a routine, uncomplicated pregnancy with the most appropriate next step in prenatal screening or management.

  • A pregnant woman at 12 weeks of gestation presenting for early risk assessment.Assessment of fetal nuchal translucency combined with maternal serum PAPP-A and free beta-hCG.
  • A pregnant woman at 25 weeks of gestation presenting for mid-pregnancy metabolic evaluation.Administration of a 50-g oral glucose load followed by a 1-hour venous glucose measurement.
  • An Rh(D)-negative pregnant woman at 28 weeks of gestation with an uncomplicated clinical course.Intramuscular administration of prophylactic anti-D immune globulin to prevent alloimmunization.
  • A pregnant woman at 36 weeks of gestation preparing for term labor and delivery.Collection of a swab from the lower vagina and rectum to screen for colonization requiring intrapartum prophylaxis.

Cevap

The correct pairings align 12 weeks with aneuploidy screening (nuchal translucency and serum markers), 25 weeks with gestational diabetes screening (50-g glucose load), 28 weeks with prophylactic anti-D immune globulin for Rh(D)-negative status, and 36 weeks with rectovaginal Group B Streptococcus screening.
Routine prenatal care follows a standardized timeline to maximize maternal and fetal safety. First-trimester aneuploidy screening (nuchal translucency, PAPP-A, beta-hCG) must be performed between 11 and 14 weeks. Gestational diabetes screening is conducted between 24 and 28 weeks because human placental lactogen and other hormones cause peaking insulin resistance during this period. Anti-D immune globulin is routinely administered at 28 weeks to Rh(D)-negative women to prevent maternal alloimmunization prior to delivery. Group B Streptococcus screening is performed via rectovaginal culture at 36 to 38 weeks because colonization status fluctuates; testing close to the expected time of delivery provides the highest predictive value for the need of intrapartum antibiotic prophylaxis.

Adım Adım Çözüm

1
Determine the appropriate screening for a patient at 12 weeks of gestation.
Match with assessment of fetal nuchal translucency and serum PAPP-A/beta-hCG.
First-trimester aneuploidy screening is specifically timed for the 11 to 14 week window to evaluate chromosomal risk.
2
Determine the appropriate screening for a patient at 25 weeks of gestation.
Match with administration of a 50-g oral glucose load.
Universal screening for gestational diabetes is optimally performed between 24 and 28 weeks when placental hormone-driven insulin resistance becomes clinically significant.
3
Determine the appropriate intervention for an Rh(D)-negative patient at 28 weeks of gestation.
Match with intramuscular administration of prophylactic anti-D immune globulin.
Routine prophylaxis is given at 28 weeks to provide passive immunity against alloimmunization during the third trimester, when the risk of fetomaternal hemorrhage increases.
4
Determine the appropriate screening for a patient at 36 weeks of gestation.
Match with collection of a rectovaginal swab for Group B Streptococcus.
Universal GBS screening is conducted between 36 and 38 weeks because colonization is transient, and testing within 5 weeks of expected delivery most accurately predicts colonization at the time of birth.

Anahtar Kavram

Routine Prenatal Screening Timeline
Tahmini Süre:1m 0s
Bu soruyu puanla

Konular

Normal Pregnancy and Prenatal Care

Bu konudan daha fazla soru